Kornimate/medical-research-clean huggingface dataset:
associations between dietary intake and cardiometabolic and gut microbiota outcomes

Conditions: Cardiometabolic Risk Factors; Gut -Microbiota; Skin Condition; Cognitive Ability, General; Sleep Quality

Summary: this cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in singapore adults.

diet plays a crucial role in maintaining overall health, and changes in dietary patterns are increasingly recognized as major contributors to chronic disease development. inadequate dietary intake and poor diet quality have been linked to increased risks of cardiometabolic diseases and disruptions in gut microbiota composition. however, most studies investigating these associations have been conducted on western populations, and there is a lack of research focusing on asian populations. given the genetic, metabolic, and dietary differences between western and asian populations, examining these associations in an asian population is essential for a deeper understanding of population-specific risk factors and health outcomes. therefore, there is an urgent need to assess the associations between dietary intake, cardiometabolic health, and gut microbiota composition in asian population. this cross-sectional study aims to investigate the associations between dietary intake, cardiometabolic health markers, and gut microbiota composition in singapore adults. findings from this study will offer valuable insights into the relationship between diet, cardiometabolic health, and the gut microbiota in this population. in addition, this research may identify specific dietary patterns or nutrients that offer greater benefit for cardiometabolic and gut health. in turn, these findings can contribute to the improvement of current dietary guidelines aimed at promoting better cardiometabolic and gut microbiota outcomes for the broader singaporean population.

Eligibility criteria:
inclusion criteria: 1. able to give informed consent 2. adults 21-80 years old 3. english-literate 4. have venous access sufficient to allow for blood sampling as per the protocol 5. no drastic change of diet for the past 1 year 6. if taking medication, has been consistently taking antihypertensive/cholesterol-lowering/type-2 diabetic medication for more than 5 years prior to starting the study. exclusion criteria: 1. taking dietary supplements and fermented foods, which may impact the gut microbiota (e.g. antibiotics, prebiotics, probiotics, yogurt, kimchi) 2 months before starting the 1st study visit only. 2. taking dietary supplements or medications, which may impact sleep outcomes (e.g. nutritional shakes (e.g. ensure), tryptophan, 5-hydroxytryptophan or melatonin supplementations) 1 month before starting the study. 3. taking dietary supplements which may impact the eye outcomes (e.g. vitamin a, vitamin a-containing multivitamin) 2 months before starting the study.

Keywords: endothelial progenitor cells gut microbiota cardiovascular diseases risk factors moca advanced glycation end products
auditory training with speech related acoustic cues using psychophysical testing

Conditions: Deafness

Summary: in this study, the investigators will evaluate whether auditory training with speech-related acoustic features in psychophysical testing will help ci subjects improve speech recognition. the primary endpoint is the speech recognition measures.


Eligibility criteria:
inclusion criteria: * native speakers of english * cochlear nucleus cochlear implant users or advanced bionics users * postlingually deafened * has had device experience for at least one year * can be child or adult at the time of enrollment exclusion criteria: * none
sequent extended study

Conditions: Coronary Artery Disease; Ischemic Heart Disease

Summary: multicenter, prospective, non-randomized, post-market clinical follow-up (pmcf) study to confirm and support the clinical safety and performance of sequent please neo to meet eu medical device regulation (mdr) requirements in all the consecutive patients treated with sequent please neo.

the objective of this multicenter, prospective, non-randomized, postmarket clinical follow-up(pmcf) study is to confirm and support the clinical safety and performance of the sequent please neo in a non-selected, real word population under daily clinical practice when used as intended by the manufacturer to meet eu medical device regulation requirements for post-market clinical follow-up.

Eligibility criteria:
inclusion criteria: * patients treated with sequent please neo according to routine hospital practice and following instruction for use. * informed consent signed. exclusion criteria: * patient life expectancy less than 12 months. * contraindication for antiplatelet therapy. * not meet inclusion criteria.

Keywords: mdr (medical device regulations) pmcf (post-market clinical follow-up) paclitaxel eluting coronary balloon dilatation catheter
hd-tdcs as a treatment for chronic tinnitus

Conditions: Tinnitus, Subjective

Summary: transcranial direct current stimulation (tdcs) aims to induce cortical plasticity by modulating the activity of brain structures. the broad stimulation pattern, which is one of the main limitations of tdcs, can be overcome with the recently developed technique called high-definition tdcs (hd-tdcs). the objective of the current study is to investigate the effect of hd-tdcs on tinnitus in a large patient cohort.


Eligibility criteria:
inclusion criteria: * chronic, subjective, non-pulsatile tinnitus * met the criteria for hd-tdcs safety exclusion criteria: * a middle ear pathology * another tinnitus treatment ongoing

Keywords: tinnitus neuromodulation non-invasive brain stimulation transcranial direct current stimulation large cohort high-definition tdcs
autologous mesenchymal stromal cells and islet co-transplantation in tp-iat

Conditions: Chronic Pancreatitis; Mesenchymal Stem Cells

Summary: this is a clinical trial for chronic pancreatitis (cp) patients undergoing total pancreatectomy with islet autotransplantation (tp-iat). participants will be randomized to either bone marrow-derived mesenchymal stem cells (mscs) or control with the standard of care. participants will be followed for one-year post-transplant.

this will be a randomized, controlled clinical trial for cp patients scheduled to undergo a tp-iat surgery. those who are consented will be randomized into one of three groups. one group will receive islet transplantation alone, a placebo. the other two groups will receive islets plus autologous bone marrow-mscs at two different doses (20x10\^6/patient, or 50x10\^6/patient). the tp-iat procedure will remain as routinely performed. patients will be followed for12 months post-transplantation, having 3 follow-up visits scheduled on days 90, 180, and 365 after the transplant. the primary endpoint will be a change in islet function from baseline to 12 months post-transplantation as measured by the c-peptide area under the curve following a mixed meal tolerance test. potential effects of mscs on glycemic control, pain relief, quality of life, and adverse events will be evaluated at each follow-up visit.

Eligibility criteria:
inclusion criteria: * diagnosis of cp and scheduled for tp-iat; * ≥18 years old; * diabetes with hba1c \<12%. exclusion criteria: * patients who are under immunosuppression; * pregnant and breastfeeding women. * patients who have liver damage based on alt, ast, and total bilirubin levels (\>3 times normal levels);

Keywords: total pancreatectomy tp-iat
a clinical study to assess the effect of a supplement on digestive health, overall well-being, and participant experience.

Conditions: Digestive System Disease

Summary: the study aims to evaluate the effectiveness of a dietary supplement (greens powder), on improving digestive health, quality of life, energy levels, and satiety over a 14-day period. participants, aged 18-65 and experiencing mild digestive issues, will consume the greens powder daily and report outcomes through diaries and questionnaires.


Eligibility criteria:
inclusion criteria: * male or female. * aged 18-65 years. * willing to comply with study requirements. * no known allergies to the ingredients listed in the product. * self-reported mild digestive issues (e.g., occasional bloating, stomach discomfort, occasional constipation, or occasional diarrhea). * generally healthy - do not live with any uncontrolled chronic disease . exclusion criteria: * pre-existing chronic conditions that would prevent adherence to the protocol, including oncological and psychiatric disorders. * known severe allergic reactions that require an epi-pen. * women who are pregnant, breastfeeding, or attempting to conceive. * history of severe diagnosed digestive disorders (e.g., ibs, ibd, crohn's disease) or gastrointestinal-tract surgeries. * unwillingness to follow the study protocol. * invasive medical procedure within the last three weeks or planning one during the study period. * history of substance abuse. * current participation or planning to participate in another research study. * regular consumption of probiotics, fiber, or prebiotic supplements within 3 weeks of the study. * regular intake of medications that may interfere with the study or study product (e.g., anticoagulants, laxatives, sedatives, beta-blockers, anti-acids) .

Keywords: dietary supplements digestive health well-being energy levels
radiomics and radiogenomics models to predict molecular integrated risk classes and prognostic factors in endometrial cancer.

Conditions: Endometrial Cancer

Summary: the aim is to develop radiogenomics models to stratify patients into three main risk categories (favorable, intermediate, and unfavorable) according to the promise model (9) and use these models to predict the most prognostically relevant ec histopathological features (i.e. figo stage, degree of tumor differentiation, histotype, lvsi status, myometrial and cervical invasion, lymph node metastases). these models would support clinicians in personalizing surgical and adjuvant treatment choice among the options considered by the international guidelines.


Eligibility criteria:
inclusion criteria: * pathologically confirmed diagnosis of primary endometrial cancer (endometrioid, clear cell, serous, mixed, any grade) * figo stage ia-ib * formalin-fixed, paraffin-embedded (ffpe) tissue at the diagnosis available - availability of preoperative mri scans in dicom (.dcm) format * availability of preoperative us images in dicom (.dcm) format * availability of preoperative ct-scan images in dicom (.dcm) format (optional) * available clinical information (e.g. baseline information, surgery, adjuvant therapy, median follow up period 24 months) exclusion criteria: * metastatic cancer to the uterus (not primary ec) * uterine sarcoma * conservative surgery * figo stage \> ii * formalin-fixed, paraffin-embedded (ffpe) tissue at the diagnosis not available * patients without available mri, us or ct-scan images on digital media * clinical information not available or incomplete * any other malignancy in the previous 5 years or synchronous * patients aged under 18 years

Keywords: radiomic ultrasound mri molecular sequencing radiogenomic omic analyses molecular classification
comprehensive study of duchenne muscular dystrophy at sohag university hospital

Conditions: Duchenne Muscular Dystrophy

Summary: muscular dystrophies are a heterogenous group of inherited muscular disorders characterized by progressive muscle weakness. historically, these disorders are difficult to treat. in the last three decades, there is a great progress in molecular and genetic basis of these disorders; early diagnosis is achievable with proper clinical recognition and advanced genetic testing .duchenne muscular dystrophy (dmd) is a neuromuscular muscular x-linked recessive disorders that belong to a group of disorders known as dystrophinopathies. dmd characterized by a progressive degeneration of skeletal muscles, with symptoms that manifest early, at around 3 years, causing loss of ambulation within the 13 years of life, followed by cardiac complication (e.g., dilated cardiomyopathy and arrhythmia) and respiratory disorders, including chronic respiratory failure. the unique medical treatment available is steroid therapy, which appears to prolong walking capacity by at least two years. thus, besides medical treatment, the physical therapy in multidisciplinary care is imperative for alleviating muscle atrophy, skeletal deformities, and motor function deterioration.


Eligibility criteria:
inclusion criteria: 1. age of onset between 3- and 18-year-old 2. typical clinical manifestation of duchenne muscular dystrophy 3. clinical manifestation confirmed by specific biochemical analysis or by genetic testing who presented to pediatric department and neurology outpatient clinic during the period of study. exclusion criteria: 1. children with another congenital muscular dystrophy 2. children with other types of myopathies 3. presence of cns disorders such as brain insult \& spinal muscular atrophy 4. female gender
complex-posttraumatic stress disorder in urban egypt: pilot testing of a culturally-adapted evidence-based treatment manual and development of a culture-specific diagnostic

Conditions: Complex Post-Traumatic Stress Disorder

Summary: background: the cptsd diagnosis presented in the icd-11 is supposed to provide core and culturally invariant symptoms, which is supported by recent research. yet, evidence also shows the necessity of integrating culture-specific symptoms in intervention and diagnostic tools to enhance the validity and efficacy of such diagnoses and therapeutic interventions. along with cultural aspects, there are relevant structural aspects e.g., economic, and social inequalities, which impact mental health. these aspects remain understudied in low middle income countries like egypt, where there are considerable rates of violence. aims: the project aims to i) culturally adapt and pilot test the therapeutic manual estair/mpe in urban egypt, and ii) to pilot test a cultural and structural module for the diagnostic assessment of cptsd among the same target population. the objective is to assess the feasibility, acceptability, and initial impact on clinical outcomes of both the manual and diagnostic modules. methods: in earlier phases, the project gathered qualitative data from key informants on the cultural and structural dimensions of cptsd in urban egypt. using the collected data, investigators culturally adapted this intervention and developed a diagnostic cultural module. subsequently, the investigators will pilot-test it in four groups of five participants each, 20 participants in total. the project intends to collect both quantitative and qualitative measures to explore determined outcomes and analyze them accordingly.

for further information, please see the attached protocol.

Eligibility criteria:
inclusion criteria: * egyptian * 18 years of age or older * literate, can give written or oral consent * history of severe and/or prolonged trauma, and screen positive for cptsd * reside in any other major city exclusion criteria: * imminent risk of suicide, psychotic symptoms, and/or severe alcohol and/or drug abuse * have been in therapy before (i.e., completed more than 5-10 sessions of psychotherapy)
exploratory clinical study of autologous tumor-infiltrating lymphocyte injection (gt201) for advanced gynecologic tumors

Conditions: Solid Tumor

Summary: this study is a single-center, single-arm phase i clinical trial. a total of 24\~26 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study. an "autologous tumor-infiltrating lymphocyte therapy" dosing regimen consisting of lymphodepleting chemotherapy (fc regimen: cyclophosphamide + fludarabine), infusion of autologous tumor-infiltrating lymphocyte injection, and interleukin-2 injection will be used.the study process is divided into: screening period, sampling and production period, clearing and chemotherapy period, treatment and observation period, and follow-up period


Eligibility criteria:
inclusion criteria: * 1.voluntarily enrolled in the study, signed an informed consent form, and willing and able to comply with the study protocol. 2.patients with advanced cervical cancer, ovarian cancer, endometrial cancer and other gynecological tumors who have progressed or are intolerant to at least first-line therapy, or who are not suitable for existing first-line therapy. 3.at least one lesion (preferably superficial lymph nodes) that has not been treated with radiation, has not received other local therapies, has access to tumor tissue, and can isolate at least a mass ≥ 1.0 g of tissue mass (either single lesion source or multiple lesions combined) for the preparation of autologous tumor-infiltrating lymphocytes. 4.eastern collaborative oncology group (ecog) physical fitness status score of 0 or 1. exclusion criteria: * 1.failure of surgery and/or radiation therapy to relieve spinal cord compression is not eligible for enrollment. 2.people with uncontrolled tumor-related pain as judged by the investigator. 3.risk of major bleeding as assessed by investigators. 4.have interstitial pneumonia or clinically significant active pneumonia at screening, or other respiratory disease that severely affects lung function. 5.any active autoimmune disease 14 days prior to clear lymphatic chemotherapy, history of autoimmune disease, or disease requiring systemic steroid hormone or immunosuppressive drug therapy . 6.history of allergic reaction to any component of the drugs to be used in the study (including but not limited to autologous tumor infiltrating lymphocytes, cyclophosphamide, fludarabine, interleukin-2, dimethyl sulfoxide (dmso), human serum albumin (hsa), dextran-40, antibiotics (beta-lactam antibiotics, gentamicin)); 7.women who are pregnant or breastfeeding;
impact of achilles tendon ruptures: cross-sectional analysis

Conditions: Achilles Tendon Rupture

Summary: this project will assess the clinical outcomes of individuals completing rehabilitation for their achilles tendon rupture at the university hospitals of leicester. patients attending the achilles tendon rupture clinic or rehabilitation classes will be asked to complete ultrasound imaging, strength testing and questionnaires. this will provide an insight into the rehabilitation outcomes of a broad range of patients at each rehabilitation timepoint.

this study will measure the recovery of participants following achilles tendon rupture. measurements will capture individual participants at each rehabilitation time point following achilles tendon rupture. these time points include following rupture (week 0), after 8 weeks, 10 weeks, 4 months, 6 months and 1 year. the measurements include an ultrasound tissue characterisation scan, isometric (static) strength test and heel raise test. in addition questionnaires will be completed by participants at each time point. questionnaires include the achilles tendon rupture score, hospital anxiety and depression scale, eq5d (a health related quality of life measure), international physical activity questionnaire, tampa scale for kinesiophobia and the pain catastrophising scale.

Eligibility criteria:
inclusion criteria: * able to provide informed consent * 16 years of age or above exclusion criteria: * inability to provide informed consent due to cognitive impairment * inability to provide informed consent as unable to understand sufficient english
effects of leds on memory in tbi patients

Conditions: Traumatic Brain Injury

Summary: the purpose of the study is to investigate whether transcranial, high-intensity led placed on the scalp can improve working memory in people who have sustained a concussion with lingering effects or a mild brain injury.

this is a four month, outpatient, single center study investigating whether transcranial, high intensity led applied outside the skull can improve frontal lobe executive function and working memory in participants with chronic, mild traumatic brain injury (tbi), with or without mild posttraumatic stress disorder (ptsd), due to closed head injury. participants will sign the informed consent form(icf) before neuropsychological screening test are administered. if the participant's neuropsychological screening test scores meet the inclusion/exclusion criteria and the participant meets the other inclusion/exclusion criteria, then he/she will be tested again on the tests that are part of the neuropsychological outcome measures, the week before the transcranial led treatments, and during the week after the last led treatment and again at one and two months after the last led treatment. treatment with transcranial led will be for 6 weeks. participants will be treated three times per week: monday, wednesday and friday. a total of 18 transcranial led treatments will be administered.

Eligibility criteria:
inclusion criteria: * male or female, ages 18-65 * sustained a mild traumatic brain injury(mtbi) at least 6 months ago * mtbi is defined as \< 30 minutes loss of consciousness and \<30 minutes, post trauma amnesia * since the injury patient continues having problems with memory and thinking ability exclusion criteria: * younger than 18 or older than 65 * mtbi occured less than 6 months ago * moderate to severe traumatic brain injury (tbi) * non-closed head injury * presence of craniotomy, craniectomy, or ventriculoperitoneal shunt * non-english speaking subjects - neuropsychological tests only in english * neuropsychological screening test scores not at least 2 sd below norm on one of the neuropsychological tests or not 1 sd below norm on at least two of the tests administered during screening)

Keywords: mild traumatic brain injury mild tbi mtbi